Drug interactions
Ivosidenib + Octreotide
Severity: Major
Ivosidenib and Octreotide: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ivosidenib is labeled for QTc prolongation, and octreotide may add to this through bradycardia and repolarization effects. The combination may increase the risk of torsades de pointes.
What this interaction means in plain words
Ivosidenib and Octreotide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Ivosidenib belongs to Oncology; Octreotide belongs to Endocrine.
Why it happens
Additive QTc prolongation.
What to do
Avoid if possible; if both are needed, monitor ECG and electrolytes closely and reduce or interrupt ivosidenib if QTc becomes markedly prolonged.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ivosidenib and Octreotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Octreotide
Other interactions of Ivosidenib
- Alfuzosin + Ivosidenib Major
- Amiodarone + Ivosidenib Major
- Amisulpride + Ivosidenib Major
- Amitriptyline + Ivosidenib Major
- Amobarbital + Ivosidenib Major
- Anagrelide + Ivosidenib Major
Frequently asked questions
Can I take Ivosidenib with Octreotide?
MediHelp rates the interaction as major. Ivosidenib and Octreotide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Ivosidenib is labeled for QTc prolongation, and octreotide may add to this through bradycardia and repolarization effects. The combination may increase the risk of torsades de pointes.
How serious is the interaction between Ivosidenib and Octreotide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible; if both are needed, monitor ECG and electrolytes closely and reduce or interrupt ivosidenib if QTc becomes markedly prolonged.
What other medicines interact with Octreotide?
MediHelp also lists interactions of Octreotide with, for example, Adagrasib, Amisulpride, Arsenic trioxide. The full list is on the Octreotide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
